(Circulation. 1999;99:1084-1090.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Tranilast Suppresses Vascular Chymase Expression and Neointima Formation in Balloon-Injured Dog Carotid Artery
From the Department of Pharmacology, Osaka Medical College (N. Shiota, S.T., I.M, H.S., M.M.), Takatsuki, Japan; the Department of Pharmacology, Shimane Medical University (H.O.), Izumo, Japan; and Second Research Laboratories, Kissei Pharmaceutical Co, Ltd (N. Shibata), Nagano, Japan.
Correspondence to Naotaka Shiota, MD, PhD, Department of Pharmacology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Activation of vascular chymase plays a major role in myointimal hypertrophy after vascular injury by augmenting the production of angiotensin (ANG) II. Because chymase is synthesized mainly in mast cells, we assumed that the chymase-dependent ANG II formation could be downregulated by tranilast, a mast cell–stabilizing antiallergic agent. We have assessed inhibitory effects of tranilast on neointima formation after balloon injury in the carotid artery of dogs, which share a similar ANG II–forming chymase with humans, and further explored the pathophysiological significance of vascular chymase.
Methods and Results—Either tranilast (50 mg/kg BID) or vehicle was orally administered to beagles for 2 weeks before and 4 weeks after balloon injury. Four weeks after the injury, remarkable neointima was formed in the carotid arteries of vehicle-treated dogs. Chymase mRNA levels and chymaselike activity of vehicle-treated injured arteries were increased 10.2- and 4.8-fold, respectively, those of uninjured arteries. Angiotensin-converting enzyme (ACE) activity was slightly increased in the injured arteries, whereas ACE mRNA levels were not. Tranilast treatment completely prevented the increase in chymaselike activity, reduced the chymase mRNA levels by 43%, and decreased the carotid intima/media ratio by 63%. In vehicle-treated injured arteries, mast cell count in the adventitia showed a great increase, which was completely prevented by the tranilast treatment. Vascular ACE activity and mRNA levels were unaffected by tranilast.
Conclusions—Tranilast suppressed chymase gene expression, which was specifically activated in the injured arteries, and prevented neointima formation. Suppression of the chymase-dependent ANG II–forming pathway may contribute to the beneficial effects of tranilast.
Key Words: angiotensin • leukocytes • restenosis • angiogenesis • polymerase chain reaction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Percutaneous transluminal coronary angioplasty (PTCA) is an established therapy for obstructive coronary artery diseases. However, its long-term efficacy is limited by frequent occurrence of restenosis.1 Migration and proliferation of smooth muscle cells (SMCs) with subsequent formation of neointima are considered important in late stenosis after PTCA.1 In this process, angiotensin (ANG) II supposedly plays a major role.2 Involvement of ANG II in the pathogenesis of restenosis was further confirmed by the facts that ACE inhibitors as well as ANG II receptor antagonists effectively prevented neointima formation in balloon-injured rats.3 4 On the basis of these experimental findings, ACE inhibitors were applied in clinical trials for preventing restenosis after PTCA. However, ACE inhibitors proved to be ineffective on human restenosis.5 6
Such species differences in the ACE inhibitor effects on neointima suggested the presence of alternative ANG II–forming pathways in humans. Previously we demonstrated that chymase contributed to ANG II formation in human, monkey, and dog vascular tissues.7 8 9 10 11 Chymases of these species cleave the Phe8-His9 bond of ANG I and produce ANG II efficiently.7 8 9 10 11 12 13 In contrast, rat chymase (rat mast cell protease I [RMCP-1]) hydrolyzes the Tyr4-Ile5 bond to yield inactive fragments.14 Therefore the vascular ANG II–forming system in primates and dogs is quite different from that in rats.9 Such species differences in the vascular ANG II–forming systems may explain the differential effects of ACE inhibitors on myointimal hypertrophy. To confirm our hypothesis, we established balloon-injured models of dogs that have the dual ANG II–forming systems like that in humans and compared the effects of an ACE inhibitor and an ANG II receptor antagonist. Balloon injury remarkably activated canine vascular chymase,10 and an ANG II receptor antagonist substantially prevented neointima formation, whereas an ACE inhibitor did so only modestly.15 These results indicate that chymase contributes to the pathogenesis of intimal hyperplasia by augmenting the local ANG II production to a greater extent than does ACE.
Chymase is synthesized mainly in connective tissue–type mast cells and secreted into the interstitium. Some antiallergic drugs are capable of stabilizing mast cell functions. Therefore the chymase-dependent ANG II formation may be attenuated by such agents that suppress mast cell activation. Tranilast, N-(3,4-dimethoxycinnamoyl) anthranilic acid, is an antiallergic drug that has clinical indications such as bronchial asthma, allergic rhinitis, atopic dermatitis, and keloid and hypertrophic scar.16 17 18 19 Thus we investigated in dogs whether tranilast inhibits neointima formation and whether vascular chymase is involved in the pathogenesis of neointimal hypertrophy after balloon injury.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Balloon Catheterization of Carotid Arteries
Twelve male beagles weighing 9 to 12 kg (Nihon Nosan, Yokohama, Japan) underwent balloon catheterization as described previously with modification.10 15 Under pentobarbital anesthesia, the anterior thyroid arteries of both right and left sides were exposed. Through the right side artery, a balloon catheter (3F, VERMED) was inserted into the right common carotid artery with caution to minimize unintended surgical damages to the outer wall of the common carotid artery and pushed further into the proximal direction. The balloon then was inflated with water to distend the common carotid artery and pulled back.15 After this procedure was repeated thrice, the catheter was removed and the insertion port was ligated. The left common carotid artery was kept intact and used as the control. All other procedures including heparin and antibiotic dosing were performed as previously noted.15
Drug Administration
The beagles were placed randomly into 2 groups. One group (n=5)
was orally given tranilast (50 mg/kg BID; Kissei Pharmaceutical) for 2
weeks before balloon injury and for 4 weeks thereafter throughout the
experimental period. The other group (n=7) received the vehicle during
the same period. Experimental procedures were in accordance with the
Guide for the Care and Use of Laboratory Animals (Animal Research
Laboratory, Osaka Medical College).
Histological Analysis
Four weeks after ballooning, the animals were given an overdose
of pentobarbital and exsanguinated by heart excision. The common
carotid arteries of both sides were excised and divided into 5 parts,
respectively. From each part, a small segment (3 mm long) was
obtained and fixed with neutral buffered formalin, paraffin-embedded,
and cut into 3-µm-thick sections. The sections were stained with
elastica–van Gieson, and cross-sectional areas of intima, media,
adventitia, and lumen were quantified with an image analysis
system (LUZEX 3; Nikon Optical Co). The neointimal area was
traced between the internal elastic lamina (IEL) and the luminal edge
of neointima. The medial area was traced between the IEL
and the external elastic lamina (EEL). The adventitial area was defined
from the EEL outward to the border between the inner dense and the
outer loose connective tissues. These measures were the average of 5
different segments for each individual artery. The proliferative
activity was assessed by proliferating cell nuclear antigen (PCNA)
expression and cell density of each vascular wall compartment. Sections
were incubated with primary antibody to PCNA (PC10, 1:150 dilution,
DAKO JAPAN) overnight at 4°C and then with a peroxidase-conjugated
rabbit anti-mouse immunoglobulin (1:50 dilution, DAKO JAPAN) for 2
hours at 20°C. Sections were visualized with DAB substrate (Wako Pure
Chemical) followed by counterstain with Carazzi's hematoxylin. Cell
density was determined by counting the total number of counterstained
nuclei in 3 randomly chosen 0.1-mm2 regions of
neointima, media, and adventitia from each section. The
PCNA index reflects the percentage of PCNA-positive cells.
Adventitial fibrosis was analyzed with Azan-stained sections. For analyzing adventitial angiogenesis, sections were stained with primary antibody to factor VIII (1:200 dilution, DAKO JAPAN) overnight at 4°C and then with a peroxidase-conjugated swine anti-rabbit immunoglobulin (1:50 dilution, DAKO JAPAN) for 2 hours at 20°C. The number of vasa vasorum in the total adventitial area was counted and expressed as density (vessels/mm2). The number and localization of mast cells were estimated with toluidine blue–stained sections. Because almost all mast cells are located in the adventitia, its density was expressed as total mast cell count in adventitia/total adventitial area. Correlation analyses were performed between (1) intimal and adventitial areas, (2) intimal area and mast cell density, and (3) adventitial area and mast cell density for the injured carotid arteries of vehicle-treated and tranilast-treated dogs.
Measurement of ACE and Chymaselike Activities
ACE activity was measured with hippuryl-His-Leu substrate
(Peptide Institute).10 Chymaselike activity was measured
with ANG I substrate as described
previously.20
Measurement of Plasma Renin Activity and Plasma ANG II
Content
Blood samples for measurement of plasma renin activity (PRA) and
plasma ANG II content were taken into chilled tubes containing 5
mmol/L EDTA and 1 mmol/L PMSF (final concentrations) 2 hours after
the final dosing. PRA was measured by radioimmunoassay with a
commercial kit (SRL). Plasma ANG II content was measured by
radioimmunoassay after fractionation by reverse-phase
high-performance liquid
chromatography,21 with the use of
anti–ANG II antiserum (a gift from Dr S. Kim, Osaka City
University).
Quantitative Reverse-Transcriptase Polymerase Chain Reaction
Analysis
Chymase and ACE mRNA levels of carotid arteries were determined
with quantitative reverse-transcriptase polymerase chain reaction (PCR)
analysis described previously with
modifications.20 The PCR primers for dog chymase were
selected according to the dog chymase cDNA sequence22
(sense primer: 5'-ATCCTCACTCTCCGGAA-TCACCTG-3', position
130 to 153; antisense primer: 5'-CAGAACCTTATTGATCCAGGGCCG-3', position
741 to 718). The competitor DNA for dog chymase was obtained by
inserting a 360-bp external DNA fragment at the BstEII site.
For determination of the dog ACE cDNA sequence, PCR primers were
designed at first based on the human ACE cDNA
sequence23 (sense primer:
5'-AACGCCCTGCTAAGCAACATG-3', position 443 to 463; antisense primer:
5'-CATCGAGGTTGGGCTTGTCTG-3', position 944 to 924). The PCR product
was subcloned, and a 504-bp dog ACE cDNA sequence was determined, then
the specific PCR primers for quantification of dog ACE transcripts were
designed according to the already-determined dog ACE cDNA sequence
(sense primer: 5'-AACAGGATCTATTCCACAGCC-3', position 464 to 484;
antisense primer: 5'-AGGCACCATCATGTCATAGAG-3', position 919 to 899).
The competitor DNA for dog ACE was prepared by inserting a 360-bp
external DNA fragment at the BstXI site. The amplification
conditions for dog chymase were 94°C for 1 minute, 65°C for 1
minute, and 72°C for 1 minute over 40 cycles. The conditions for dog
ACE were 94°C for 1 minute, 60°C for 1 minute, and 72°C for 1
minute over 40 cycles. The integrated density of PCR products was
measured as described
previously.20
Measurement of Plasma and Vascular Tissue Concentration of
Tranilast
Plasma samples were obtained 2 and 12 hours after drug
administration the day before the euthanasia. Plasma aliquots (100
µL) were incubated for 10 minutes at room temperature with 200 µL
of internal standard solution (N-cinnamoylanthranilic acid,
100 µg/mL) and 2 mL of ethanol and centrifuged at 3000 rpm
for 10 minutes. Supernatants were evaporated to dryness, and the
residues were resuspended with 150 µL of 50% acetonitrile and 10
µL of acetic acid and then fractionated by reverse-phase
high-performance liquid chromatography. Common
carotid arteries of both sides were dissected 2 hours after the final
dosing on the day of euthanasia. The excised arteries (200 mg) were
minced and homogenized in 1 mL of 0.02 mol/L NaOH and 200
µL of internal standard solution. The homogenate was
incubated for 30 minutes at room temperature with 3 mL of acetonitrile
and centrifuged at 3000 rpm for 10 minutes. The supernatant was
processed in the same manner as for plasma. The final recovery of
tranilast from tissues or plasma after overall procedures
was>90%.
Direct Effect of Tranilast on Chymase Activity In
Vitro
The direct inhibitory effect of tranilast on the
catalytic activity of chymase was analyzed with purified human
chymase (from gastroepiploic arteries24 ) and dog carotid
arterial preparations. One milliunit of human chymase was
preincubated with 10-6,
10-5, 10-4, and
10-3 mol/L tranilast in 20 mmol/L Tris-HCl
buffer (pH 8.0) containing 0.5 mol/L KCl and 0.1% (vol/vol) Triton
X-100 for 1 hour at 37°C and then incubated with 100 µmol/L
ANG I for 10 minutes. ANG II was determined as mentioned earlier. After
tissue extract from dog carotid artery was preincubated with the same
series of concentrations of tranilast for 1 hour at 37°C, its
chymaselike activity was measured as described earlier.
Statistical Analyses
All numerical data are expressed as mean±SEM. Significant
differences between the means of different groups were evaluated by
Student's t test for unpaired data and by the modified
t test for multiple comparison (Tukey's method) after 2-way
ANOVA. Simple linear regression was used to determine correlation
between several morphological indexes mentioned in the
"Histological Analysis" section.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effect of Tranilast on Vascular Remodeling
The balloon injury elicited remarkable neointima formation (Figure 1A
). Tranilast markedly
prevented this neointima formation and decreased the
intima/media ratio of injured arteries by 63% (P<0.05,
Figures 1B and 2). The lumen area
of vehicle-treated injured arteries (1.00±0.09
mm2, n=7) was smaller than that of
vehicle-treated uninjured arteries (1.56±0.17
mm2, n=7, P<0.05), indicating luminal
stenosis. After treatment with tranilast, luminal
stenosis as well as neointima formation were
prevented: The lumen area of injured arteries (1.66±0.21
mm2, n=5) was not significantly different from
that of uninjured arteries (1.87±0.20 mm2,
n=5). The cross-sectional area of the media was not altered by the
injury, nor differed between the injured arteries of the
vehicle-treated and the tranilast-treated dogs. After the injury,
fibrosis (Figure 1G), angiogenesis (Figure 1I), and an
increase in mast cell count (Figure 1D) were observed in the
adventitia. The adventitial area/medial area ratio of injured arteries
in vehicle-treated dogs was 1.9 times that of the uninjured arteries
(P<0.05, Figure 2). In the tranilast-treated group,
adventitia/media ratio did not differ between injured and uninjured
arteries (Figure 2). Adventitial fibrosis was analyzed
with Azan-stained sections. In vehicle-treated dogs, the blue-stained
area in the adventitia of injured arteries (3.82±0.50
mm2, n=7) was 2.2 times that of uninjured
arteries (1.72±0.20 mm2, n=7,
P<0.05). In tranilast-treated dogs, the blue-stained area
in the adventitia of injured arteries (2.15±0.21
mm2, n=5) did not significantly differ from that
of uninjured arteries (1.76±0.28 mm2, n=5).
In vehicle-treated dogs, the vasa vasorum density in injured arteries
(60.4±8.5 vessels/mm2, n=7) was 1.5 times that
of uninjured arteries (40.3±4.6 vessels/mm2,
n=7, P<0.05). In tranilast-treated dogs, vasa vasorum
density in injured arteries (46.9±2.8
vessels/mm2, n=5) was not significantly different
from that of uninjured arteries (35.9±7.3
vessels/mm2, n=5). PCNA-positive cells were found
mainly in the neointima (Figure 1E), whereas few
were found in the media and adventitia. The PCNA index in the
neointima of tranilast-treated injured arteries
(0.018%±0.011%, n=5) was significantly lower than that of
vehicle-treated injured arteries (0.35%±0.13%, n=7,
P<0.05). PCNA indexes in the media and adventitia of
vehicle-treated injured arteries were <0.05% and did not differ from
those of tranilast-treated injured arteries and uninjured arteries. The
cell density of each vascular wall compartment was not altered in
response to injury, nor differed between the injured arteries of the
vehicle-treated and tranilast-treated dogs
(Table). There were few mast cells
in uninjured vascular walls, whereas numerous cells were found in the
injured vascular wall (Figures 1D and 3A). Mast cells were located primarily in
the adventitia and occasionally seen in the outer media (Figure 1D). In the dogs treated with tranilast, mast cell density in
the injured arteries was decreased to the level of the uninjured
arteries (P<0.05, Figure 3A). Some correlation
existed between adventitial and intimal areas (r=0.388,
P=0.0026, Figure 3B), between the change in mast cell
density and the magnitude of neointima formation
(r=0.639, P<0.0001, Figure 3C), and
between the change in mast cell density and the magnitude of
adventitial thickening (r=0.756, P<0.0001,
Figure 3D).
|
|
|
|
Chymaselike and ACE Activities of Carotid Arteries and Plasma
ACE Activity
The chymaselike activity of vehicle-treated injured arteries
exhibited an increase 10.2-fold that of uninjured arteries
(P<0.05). The long-term tranilast treatment completely
suppressed the chymaselike activity of injured arteries to the normal
level (Figure 4A). The ACE activity of
vehicle-treated injured arteries was increased 1.3 times that of
uninjured arteries (P<0.05), whereas that of
tranilast-treated injured arteries was 1.2 times that of uninjured
arteries (P<0.05). Thus tranilast did not affect vascular
ACE activity (Figure 4B). The plasma ACE activity of the
tranilast-treated dogs (11.2±1.8 mU/mL, n=5) did not differ from that
of the vehicle-treated controls (10.5±0.8 mU/mL, n=7).
|
PRA and Plasma ANG II Content
The PRA (0.95±0.20 ng/mL per hour, n=5) and the plasma ANG II
content (14.6±6.3 pg/mL, n=5) of tranilast-treated dogs did not differ
from the PRA (0.84±0.38 ng/mL per hour, n=7) and the plasma ANG II
content (15.2±3.8 pg/mL, n=7) of vehicle-treated controls.
ACE and Chymase mRNA Levels of Carotid Arteries
The chymase mRNA level of vehicle-treated injured arteries
exhibited an increase 4.8-fold that of uninjured arteries
(P<0.05). Tranilast treatment blunted the increase of
chymase mRNA level in the injured arteries to 57% that for the
vehicle-treated group (P<0.05, Figure 5A), although the level still remained
significantly higher than that of the uninjured arteries after
tranilast treatment (Figure 5A). In contrast, there was no
difference in the ACE mRNA levels between the injured and the uninjured
arteries in vehicle-treated dogs (Figure 5B). Tranilast did not
affect the ACE mRNA levels of injured or uninjured arteries (Figure 5B).
|
Plasma and Tissue Tranilast Concentrations
Plasma tranilast concentrations 2 and 12 hours after its dosing on
the penultimate day of the experiment were 297±33 µmol/L and
55.0±9.2 µmol/L, respectively. Tissue tranilast concentration 2
hours after the final dosing was 32±7 nmol/g tissue in injured carotid
arteries and 29±3 nmol/g tissue in uninjured arteries.
Direct Effect of Tranilast on Chymase Activity In Vitro
Tranilast at concentrations of 10-6,
10-5, 10-4, and
10-3 mol/L inhibited the ANG II–forming
activity of purified human chymase by 2%, 4%, 7%, and 25%,
respectively. Tranilast in concentrations up to
10-3 mol/L did not inhibit the chymaselike
activity in the tissue extract of dog carotid artery.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the injured arteries, chymaselike activity and chymase mRNA level were remarkably increased, whereas a slight increase in ACE activity and no increase in ACE mRNA expression were detected. The current study demonstrated for the first time that tranilast prevented vascular chymase expression and effectively inhibited neointima formation and luminal stenosis. Our previous study showed that the vascular ANG II content doubled in the injured arteries compared with that in the uninjured arteries and that an ANG II receptor antagonist but not an ACE inhibitor prevented the neointima formation.15 In the current study, tranilast treatment did not affect plasma ANG II concentration, plasma ACE activity, or PRA. Vascular ANG II–forming activity of chymase increased 4.8-fold in vehicle-treated dogs, whereas tranilast treatment completely prevented the increase in chymase activity. Therefore, the ANG II–forming rate in local vascular tissues supposedly increased after vascular injury but returned to the normal level by tranilast treatment. Tranilast decreased significantly the intima/media ratio and the PCNA index of the neointima. Tranilast may exhibit an antiproliferative effect on neointimal cells. These results suggest that the activated vascular chymase promotes tissue remodeling by augmenting the local ANG II production in injured vascular tissues.
Long-term treatment with tranilast completely suppressed the increase of vascular chymaselike activity in vivo. However, tranilast up to a concentration of 10-3 mol/L did not directly affect the chymaselike activity in vitro. Chymase derives mainly from connective tissue–type mast cells. In the current study, mast cell density was markedly increased in the balloon-injured arteries, but such an increase was almost completely prevented by the long-term tranilast treatment. A clinical finding also showed that the mast cell counts were reduced in lesions of urticaria pigmentosa after long-term tranilast treatment.25 Mast cell count was greatly increased in the adventitia after balloon injury, but few PCNA-positive cells were there, indicating that the mast cell number might be increased primarily because of migration into the adventitia. Therefore tranilast might inhibit the mast cell migration, thereby indirectly suppressing vascular chymaselike activity. Cell-to-cell interaction between fibroblasts and mast cells through regulation of stem cell factor (SCF)/c-kit expression is essential for the development of mast cells. Tranilast is also known to downregulate the activity of fibroblasts.18 19 Although the precise mechanism is yet unknown, tranilast may inhibit the development as well as degranulation of mast cells.
In addition to neointima formation, adventitial thickening occurred in the injured arteries. PCNA-positive cells were found mainly in the neointima, whereas few were found in the adventitia. A recent study with pig balloon-injured models indicated that the PCNA index of each vascular wall compartment increased maximally 3 to 7 days after injury and returned to baseline after 28 days.26 Our study analyzed the proliferative activity of arteries 4 weeks after balloon injury, when the adventitia might become largely quiescent. Furthermore, adventitial cell density of injured arteries did not differ from that of uninjured arteries, whereas Azan-stained areas of collagen fibers increased in the adventitia of injured arteries. These results suggest that adventitial thickening can be ascribed mainly but not simply to collagen accumulation. Tranilast prevented adventitial fibrosis as well as neointimal hyperplasia. Recent observations indicated the close interaction between adventitial remodeling and neointima formation. After deep medial coronary injury, adventitial myofibroblasts migrated across the EEL toward the intima and contributed to neointima formation.27 Neointima developed also after direct adventitial manipulation alone without any endoluminal vascular injury.28 Indeed, the current study showed the correlation between intimal and adventitial thickening. Vascular adventitia consists of a variety of cells and structures, of which we focused on the development of vascular mast cells as the main source of chymase. In the adventitia, mast cell density was increased remarkably, with which the degree of neointima formation was closely correlated. Our results are supported by the others showing that mast cell counts were increased in the adventitia of the aorta and coronary artery with atherosclerotic lesions.29 The current study also showed the proliferation of vasa vasorum in the adventitia. Another report has demonstrated that perivascular angiogenesis is correlated with the degree of intimal hyperplasia.30 These findings suggest that various growth factors including ANG II which are formed in the adventitia may be delivered to the media and intima through vasa vasorum.
Tranilast has been shown to display diverse biological actions in
vitro. It inhibits (1) migration and proliferation of vascular SMCs
induced by platelet-derived growth factor and transforming growth
factor-ß1
(TGF-ß1),31 (2) collagen synthesis
by vascular SMCs and fibroblasts,19 31 32 (3) release of
TGF-ß1 from fibroblasts,19 and (4)
fibroblast proliferation.19 These cellular effects of
tranilast occurred with concentrations from
3x10-5 to 3x10-4
mol/L.19 31 Furthermore, a recent study indicated that
tranilast inhibited the ANG II binding to its type 1 receptors, with an
IC50 of 2.9x10-5
mol/L.33 In the current study, plasma tranilast
concentrations 2 and 12 hours after the final dosing were
2.97x10-4 mol/L and
5.5x10-5 mol/L, respectively, whereas tissue
tranilast contents of injured and uninjured carotid arteries at 2 hours
were 
3x10-8 mol/g tissue. Thus although
plasma tranilast concentrations reached the levels to exhibit many
biological actions up to 12 hours, its concentrations in carotid
arterial tissues scarcely reached the minimum effective
level (3x10-5 mol/L) at 2 hours when the plasma
concentration reached the peak. Although we could not exclude the
possibility that tranilast might exert its beneficial effects for
preventing intimal thickening by diverse actions described above, a
dose of >50 mg/kg (BID) is required to exhibit those actions
sufficiently in vivo. Instead, tranilast at the dose of 50 mg/kg
completely inhibited the increases in mast cell numbers and ANG
II–forming chymase activity in the injured vascular walls.
Accordingly, inhibition of chymase-dependent ANG II–forming pathway by
suppressing both activation and development of vascular mast cells may
be the most likely mechanism for exhibiting the beneficial effects of
tranilast. A recent preliminary clinical trial indicated that tranilast
(600 mg/d) treatment for 3 months effectively prevented
restenosis after PTCA.34 After an oral dose of 600
mg/d, the maximum plasma concentration of tranilast was
10-4 mol/L,33 which was near the
levels found in the current dog study. Further clinical trials of
tranilast are awaited to clarify the pathogenesis of restenosis
and to introduce new strategies for prevention of restenosis by
antiallergic drugs.
In the current study, treatment with tranilast (50 mg/kg BID) reduced the intima/media ratio of carotid arteries by 63%, which was comparable to 67% reduction by the maximum effective dose (10 mg/kg BID) of an AT1 receptor antagonist, TCV-116 (our unpublished data). Thus tranilast exhibited a strong beneficial effect comparable to the maximum dose of ANG II receptor antagonist. Although both drugs are involved in the inhibition of ANG II actions, their fundamental mechanisms of the beneficial effect may differ from each other. To clarify the true mechanism of tranilast, further studies are needed for the combined effects of these 2 agents.
In addition to chymase, mast cells express growth factors (fibroblast growth factor [FGF-2], TGF-ß, and so on) and proteases (tryptase and so on). FGF-2 is well known to be synthesized in fibroblasts, macrophages, and endothelial cells, whereas recent observations indicate that mast cells are a major source of FGF-2 in skin disorders characterized by fibrosis and angiogenesis.35 Furthermore, dog mastocytoma cells produce TGF-ß1, which promotes deposition of extracellular matrix and is associated with fibrotic conditions.36 The pathophysiological role of tryptase, another major secretory product of mast cells, remains unclear, but recent studies proved tryptase as a potent mitogen for fibroblasts.37 Tranilast completely inhibited the injury-induced increase of mast cells. Therefore it is possible that tranilast treatment may suppress these potent fibroproliferative factors together with chymase. The current study explored the beneficial effect of tranilast from the aspect of inhibition of chymase-dependent ANG II–forming pathway. However, in view of the overall functions of vascular mast cells, tranilast is potentially more beneficial than a simple ANG II receptor antagonist.
|
Acknowledgments |
|---|
This work was supported in part by grants-in-aid for encouragement of young scientists No. 07770073 and No. 08770076 (to Dr Shiota in 1995 and 1996) and a grant-in-aid for scientific research (No. 07670107 to Dr Okunishi in 1995) from the Ministry of Education, Science, Sports, and Culture, Japan.
Received May 21, 1998; revision received October 8, 1998; accepted October 22, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Lin MW, Roubin GS, King SB. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374–1387.
2. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991;18(suppl II):II-100–II-105.
3.
Powell JS, Clozel J-P, Müller RKM, Kuhn H, Hefti
F, Hosang M, Baumgartner HR. Inhibitors of
angiotensin-converting enzyme prevent myointimal
proliferation after vascular injury. Science. 1989;245:186–188.
4. Osterrieder W, Müller RKM, Powell JS, Clozel J-P, Hefti F, Baumgartner HR. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension. 1991;18(suppl II):II-60-II-64.
5.
MERCATOR Study Group. Does the new
angiotensin-converting enzyme inhibitor
cilazapril prevent restenosis after
percutaneous transluminal coronary angioplasty?
Results of the MERCATOR study: a multicenter, randomized, double-blind
placebo-controlled trial. Circulation. 1992;86:100–110.
6. Faxon DP, on behalf of the Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol. 1995;25:362–369.[Abstract]
7. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens. 1984;2:277–284.[Medline] [Order article via Infotrieve]
8. Okunishi H., Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987;149:1186–1192.[Medline] [Order article via Infotrieve]
9. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62:207–210.[Medline] [Order article via Infotrieve]
10. Shiota N, Okunishi H, Fukamizu A, Sakonjo H, Kikumori M, Nishimura T, Nakagawa T, Murakami K, Miyazaki M. Activation of 2 angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 1993;323:239–242.[Medline] [Order article via Infotrieve]
11. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;421:86–90.
12.
Reilly CF, Tewksbury DA, Schechter NM, Travis J. Rapid
conversion of angiotensin I to angiotensin II
by neutrophil and mast cell proteases. J Biol Chem. 1982;257:8619–8622.
13.
Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A.
Identification of a highly specific chymase as the major
angiotensin II-forming enzyme in the human heart.
J Biol Chem. 1990;265:22348–22357.
14.
Le Trong H, Neurath H, Woodbury RG. Substrate
specificity of the chymotrypsin-like protease in secretory granules
isolated from rat mast cells. Proc Natl Acad Sci U S A. 1987;84:364–367.
15. Okunishi H, Shiota N, Fukamizu A, Takai S, Murakami K, Miyazaki M. Angiotensin II receptor antagonist, not ACE inhibitor, prevents neointima formation on injured canine arteries. J Hypertens. 1994;12(suppl 3):S132. Abstract.
16. Komatsu H, Kojima M, Tsutsumi N, Hamano S, Kusama H, Ujiie A, Ikeda S, Nakazawa M. Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn J Pharmacol. 1988;46:43–51.[Medline] [Order article via Infotrieve]
17. Azuma H, Banno K, Yoshimura T. Pharmacological properties of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent. Br J Pharmacol. 1976;58:483–488.[Medline] [Order article via Infotrieve]
18. Isaji M, Nakajoh M, Naito J. Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5') in granulation tissue. Biochem Pharmacol. 1987;36:469–474.[Medline] [Order article via Infotrieve]
19. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992;60:91–96.[Medline] [Order article via Infotrieve]
20. Shiota N, Fukamizu A, Takai S, Okunishi H, Murakami K, Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens. 1997;15:431–440.[Medline] [Order article via Infotrieve]
21.
Kim S, Tokuyama M, Hosoi M, Yamamoto K. Adrenal and
circulating renin-angiotensin system in stroke-prone
hypertensive rats. Hypertension. 1992;20:280–291.
22. Caughey GH, Raymond WW, Vanderslice P. Dog mast cell chymase: molecular cloning and characterization. Biochemistry. 1990;29:5166–5171.[Medline] [Order article via Infotrieve]
23.
Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John
M, Tregear G, Corvol P. Two putative active centers in human
angiotensin I-converting enzyme revealed by molecular
cloning. Proc Natl Acad Sci U S A. 1988;85:9386–9390.
24. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta. 1997;265:13–20.[Medline] [Order article via Infotrieve]
25. Katoh N, Hirano S, Yasuno H. Solitary mastocytoma treated with tranilast. J Dermatol. 1996;23:335–339.[Medline] [Order article via Infotrieve]
26. Groves PH, Banning AP, Penny WJ, Lewis MJ, Cheadle HA, Newby AC. Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid model of balloon injury. Atherosclerosis. 1995;117:83–96.[Medline] [Order article via Infotrieve]
27.
Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D,
Zalewski A. Adventitial myofibroblasts contribute to
neointimal formation in injured porcine coronary
arteries. Circulation. 1996;94:1655–1664.
28. Webster WS, Bishop SP, Geer JC. Experimental aortic intimal thickening. Am J Pathol. 1974;76:245–264.[Medline] [Order article via Infotrieve]
29. Stary HC. The sequence of mast cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 1990;11(suppl E):3–19.
30. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest. 1992;89:465–473.
31. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-ß1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 1995;118:213–221.[Medline] [Order article via Infotrieve]
32. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994;107:179–185.[Medline] [Order article via Infotrieve]
33. Miyazawa K, Fukuyama J, Misawa K, Hamano S, Ujiie A. Tranilast antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells. Atherosclerosis. 1996;121:167–173.[Medline] [Order article via Infotrieve]
34. The TREAT study investigators. The impact of tranilast on restenosis following coronary angioplasty: the Tranilast Restenosis Following Angioplasty Trial (TREAT). Circulation. 1994;90(suppl I):I-652. Abstract.
35. Qu Z, Liebler JM, Powers MR, Galey T, Ahmadi P, Huang X-N, Ancel JC, Butterfield JH, Planck SR, Rosenbaum JT. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol. 1995;147:564–573.[Abstract]
36. Pennington DW, Lopez AR, Thomas PS, Peck C, Gold WM. Dog mastocytoma cells produce transforming growth factor beta 1. J Clin Invest. 1992;90:35–41.
37. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest. 1991;88:493–499.
This article has been cited by other articles:
 |
|
 |
|
  W. W. Raymond, S. Su, A. Makarova, T. M. Wilson, M. C. Carter, D. D. Metcalfe, and G. H. Caughey {alpha}2-Macroglobulin Capture Allows Detection of Mast Cell Chymase in Serum and Creates a Reservoir of Angiotensin II-Generating Activity J. Immunol., May 1, 2009; 182(9): 5770 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nachtigal, A. Ghaffar, and E. P. Mayer Galectin-3 Gene Inactivation Reduces Atherosclerotic Lesions and Adventitial Inflammation in ApoE-Deficient Mice Am. J. Pathol., January 1, 2008; 172(1): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Lavrentyev, A. M. Estes, and K. U. Malik Mechanism of High Glucose Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells Circ. Res., August 31, 2007; 101(5): 455 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jin, H. Ueda, S. Takai, Y. Okamoto, M. Muramatsu, M. Sakaguchi, N. Shibahara, Y. Katsuoka, and M. Miyazaki Effect of Chymase Inhibition on the Arteriovenous Fistula Stenosis in Dogs J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1024 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Doggrell and J. C Wanstall Vascular chymase: pathophysiological role and therapeutic potential of inhibition Cardiovasc Res, March 1, 2004; 61(4): 653 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. McPherson, Z. Luo, R. A. Brown, L. S. LeBard, C. C. Corless, R. C. Speth, and S. P. Bagby Chymase-like Angiotensin II-Generating Activity in End-Stage Human Autosomal Dominant Polycystic Kidney Disease J. Am. Soc. Nephrol., February 1, 2004; 15(2): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto, A. Wada, T. Tsutamoto, M. Ohnishi, T. Isono, and M. Kinoshita Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure Circulation, May 27, 2003; 107(20): 2555 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Takai, H. Sakonjo, K. Fukuda, D. Jin, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki A Novel Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppressed Intimal Hyperplasia after Balloon Injury J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 841 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Spiecker, I. Lorenz, N. Marx, and H. Darius Tranilast Inhibits Cytokine-Induced Nuclear Factor kappa B Activation in Vascular Endothelial Cells Mol. Pharmacol., October 1, 2002; 62(4): 856 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H Chester Mast cells feel the strain Cardiovasc Res, July 1, 2002; 55(1): 13 - 15. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tokuyama, K. Hayashi, H. Matsuda, E. Kubota, M. Honda, K. Okubo, I. Takamatsu, S. Tatematsu, Y. Ozawa, S. Wakino, et al. Differential Regulation of Elevated Renal Angiotensin II in Chronic Renal Ischemia Hypertension, July 1, 2002; 40(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Ward, A. Agrotis, P. Kanellakis, J. Hall, G. Jennings, and A. Bobik Tranilast Prevents Activation of Transforming Growth Factor-{beta} System, Leukocyte Accumulation, and Neointimal Growth in Porcine Coronary Arteries After Stenting Arterioscler Thromb Vasc Biol, June 1, 2002; 22(6): 940 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hara, K. Ono, M.-W. Hwang, A. Iwasaki, M. Okada, K. Nakatani, S. Sasayama, and A. Matsumori Evidence for a Role of Mast Cells in the Evolution to Congestive Heart Failure J. Exp. Med., February 4, 2002; 195(3): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Yau, D. P. Wilson, J. P. Werner, and P. Zahradka Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1648 - H1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Izawa, J.-i. Suzuki, W. Takahashi, J. Amano, and M. Isobe Tranilast Inhibits Cardiac Allograft Vasculopathy in Association With p21Waf1/Cip1 Expression on Neointimal Cells in Murine Cardiac Transplantation Model Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ju, R. Gros, X. You, S. Tsang, M. Husain, and M. Rabinovitch Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice PNAS, June 19, 2001; 98(13): 7469 - 7474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishimoto, S. Takai, Y. Sawada, A. Yuda, K. Kondo, M. Yamada, D. Jin, M. Sakaguchi, K. Asada, S. Sasaki, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery J. Thorac. Cardiovasc. Surg., April 1, 2001; 121(4): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ishiwata, S. Verheye, K. A. Robinson, M. Y. Salame, H. de Leon, S. B. King III, and N. A. F. Chronos Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1331 - 1337. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||